{
  "docId": "019de516-a80e-7369-bef2-cb942c391804",
  "docSlug": "7dbeec795af717930d34b2c0014ea723",
  "documentTitle": "Oculis | Results Presentation Deck | 33 slides",
  "authorId": "oculis",
  "authorName": "Oculis",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 33,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "propose_solution",
  "function": "propose_solution",
  "density": "overcrowded",
  "nDataPoints": 10,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de516-a80e-7369-bef2-cb942c391804/8",
  "deckHref": "/decks/019de516-a80e-7369-bef2-cb942c391804",
  "deckJsonHref": "/decks/019de516-a80e-7369-bef2-cb942c391804.json",
  "deckAnchorHref": "/decks/019de516-a80e-7369-bef2-cb942c391804#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.32,
        "w": 0.26,
        "x": 0.048,
        "y": 0.399
      },
      "kind": "image",
      "text": "OPTIREACH® Formulation Technology",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "29432bab-5b82-432a-a9b4-8ecd5ab0233c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.13,
        "w": 0.246,
        "x": 0.709,
        "y": 0.759
      },
      "kind": "image",
      "text": "OCS-01³",
      "attrs": null,
      "subkind": "screenshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d9f9077-83f9-441b-a99f-40debe9d7204",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.34,
        "x": 0.359,
        "y": 0.759
      },
      "kind": "list",
      "text": "OCS-01 demonstrated improvement in retinal edema / CME³\nAddresses critical unmet medical need for high-risk patients undergoing ocular surgery",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca46578f-1e95-4ca6-a3cd-0617502ed79a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.26,
        "x": 0.048,
        "y": 0.753
      },
      "kind": "paragraph",
      "text": "Longer residence time enables once daily administration in post ocular surgery¹",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1623b283-d337-485e-ad2b-ff24fa04a3ee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.26,
        "x": 0.048,
        "y": 0.33
      },
      "kind": "paragraph",
      "text": "OCS-01: High-concentration Optireach® formulation of dexamethasone (15mg/ml)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d8d6bff-e90d-4020-b8ce-9d957e2203b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.596,
        "x": 0.359,
        "y": 0.713
      },
      "kind": "paragraph",
      "text": "3/ CME Pilot Study Supports OCS-01 Treatment Potential",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8c520501-701d-4fbb-b29a-db65c684792b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.259,
        "x": 0.048,
        "y": 0.209
      },
      "kind": "paragraph",
      "text": "Unique product candidate with clinically validated MOA",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bc31a3da-344e-48f0-9851-8c35684dc8f4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.939,
        "x": 0.018,
        "y": 0.902
      },
      "kind": "source-note",
      "text": "BCVA: best corrected visual acuity; CME: cystoid macular edema; CST: central subfield thickness; DME: diabetic macular edema.\naEffect of OCS-01 was sustained through Week 12.\n1. Korenfeld M, et al. Clin Ther. 2022;44(12):1577-1587. 2. Oculis announces positive top line results from DIAMOND Stage 1 phase 3 trial in diabetic macular edema with OCS-01 eye drops..May 22, 2023.\n3. Shulman S, et al. Acta Ophthalmol. 2015;93(5):411-415.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bf9dd755-7800-4e84-b546-ce2e39d6761c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.596,
        "x": 0.359,
        "y": 0.18
      },
      "kind": "table",
      "text": "1/ Ocular Surgery Ph2 SKYGGN Trial: OCS-01 Once-daily Met Primary Endpoints¹\nActive Arms vs vehicle (N=153)\nZERO INFLAMMATION (Day 15) 51.0% vs 19.6% (P=0.0009)\nZERO PAIN (Day 4) 72.5% vs 45.1% (P=0.0049)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "05f831b6-2c1b-4ec2-aebd-70fabcd634ff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.23,
        "w": 0.596,
        "x": 0.359,
        "y": 0.409
      },
      "kind": "table",
      "text": "2/ DME Ph3 Stage 1 Diamond Trial: OCS-01 Met Primary Endpoints²\nActive Arm vs vehicle (N=148) at Week 6a\nMean Change BCVA +7.2 letters vs +3.1% (P=0.007)\n% with ≥ 3-line gain in BCVA 25.3% vs 9.8% (P=0.015)\nMean Change in CST -63.6 µm vs +5.5 µm (P < 0.0001)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7cd5e6f9-af62-4fce-b8c1-b2be1ba4b102",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.089,
        "w": 0.939,
        "x": 0.028,
        "y": 0.049
      },
      "kind": "title",
      "text": "OCS-01 – First Eye Drop Designed for Front and Back of the Eye With the potential to address multiple indications",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e0b4fa12-71c7-4d80-ab08-8b6f58c655e0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 10,
      "from": 7,
      "beatId": "bf8d92bd-d10c-44d0-8929-d028af75265a",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The document further agitates the problem by presenting detailed clinical data on the OPTIMIZE trial and current treatment limitations (slides 7-10).",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    },
    {
      "to": 24,
      "from": 8,
      "beatId": "7992b42b-1916-498c-b92e-c9642604a8e5",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents OCS-01 as a solution, highlighting its efficacy, safety, and potential value to stakeholders (slides 8-24).",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "5d7f0e87-f17e-4730-84ac-15c62ad2ef1a",
      "evidence": "The document implies the cost of inaction by highlighting the limitations of current treatments and the potential benefits of OCS-01.",
      "position": 0,
      "objective": "What are the consequences of not addressing post-ocular surgery inflammation and pain effectively?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 24,
      "from": 8,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "8c374baa-88d9-4915-a041-aab0dfbd527a",
      "evidence": "The document presents OCS-01 as a solution that addresses the needs of patients and healthcare providers.",
      "position": 1,
      "objective": "How can OCS-01 address the needs of patients and healthcare providers in ocular surgery?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.7,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}